Praxis Precision Medicines, Inc.
PRAX- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001689548
No open-market purchases or sales by Praxis Precision Medicines, Inc. insiders were filed in the last 90 days; 311 institutions reported holding it in 13F filings for Q2 2026, worth $11.3B in total; no superinvestor holds it.
- Currency
- USD
- Source
- SEC XBRL data (10-K, 10-Q, 20-F, 40-F)
- Updated
- Nov 10, 2026, 1:18 AM ET
Income statement
Each column is one fiscal year, newest first.
| Line item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Period end | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 |
| Filing | 10-K | 10-K | 10-K | 10-K | 10-K |
| Reported | Jan 6, 2026 | Jan 29, 2025 | Jan 10, 2024 | Feb 7, 2023 | Feb 28, 2022 |
| Revenue | $0 | $8.55M | $2.45M | – | – |
| Operating expenses | $326.2M | $208.7M | $128.8M | $215.0M | $167.3M |
| Research and development | $267.1M | $152.4M | $86.8M | $155.0M | $120.3M |
| Selling, general and administrative | $59.1M | $56.3M | $42.1M | $59.9M | $47.1M |
| Operating income | -$326.2M | -$200.2M | -$126.4M | -$215.0M | -$167.3M |
| Income tax | $471.0K | – | – | – | $0 |
| Net income | -$303.3M | -$182.8M | -$123.3M | -$214.0M | -$167.1M |
| EPS, basic | $-13.48 | $-10.21 | $-18.69 | $-4.64 | $-3.94 |
| EPS, diluted | $-13.48 | $-10.21 | $-18.69 | $-4.64 | $-3.94 |
| Weighted shares, basic | 22.5M | 17.9M | 6.59M | 46.1M | 42.5M |
| Weighted shares, diluted | 22.5M | 17.9M | 6.59M | 46.1M | 42.5M |
| Margins and growth | |||||
| Operating margin | – | -2340.3% | -5164.4% | – | – |
| Net margin | – | -2137.5% | -5037.9% | – | – |
| Revenue growth, year over year | −100.0% | +249.5% | – | – | – |
Balance sheet
Each column is one fiscal year, newest first.
| Line item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Period end | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 |
| Filing | 10-K | 10-K | 10-K | 10-K | 10-K |
| Reported | Jan 6, 2026 | Jan 29, 2025 | Jan 10, 2024 | Feb 7, 2023 | Feb 28, 2022 |
| Cash and equivalents | $357.3M | $215.4M | $81.3M | $61.6M | $138.7M |
| Short-term investments | $242.0M | – | – | – | – |
| Total current assets | $610.9M | $404.4M | $84.9M | $110.8M | $287.4M |
| Property, plant and equipment | $147.0K | $230.0K | $588.0K | $971.0K | $1.21M |
| Total assets | $937.9M | $483.1M | $87.9M | $115.1M | $292.7M |
| Accounts payable | $24.6M | $12.5M | $5.82M | $14.7M | $10.8M |
| Total current liabilities | $59.8M | $37.5M | $15.7M | $34.3M | $38.4M |
| Total liabilities | $59.8M | $37.7M | $18.3M | $39.0M | $41.9M |
| Shareholders' equity | $878.1M | $445.4M | $69.7M | $76.1M | $250.8M |
Cash flow statement
Each column is one fiscal year, newest first. Free cash flow is operating cash flow minus capital expenditures.
| Line item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Period end | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 |
| Filing | 10-K | 10-K | 10-K | 10-K | 10-K |
| Reported | Jan 6, 2026 | Jan 29, 2025 | Jan 10, 2024 | Feb 7, 2023 | Feb 28, 2022 |
| Operating cash flow | -$249.1M | -$131.8M | -$111.1M | -$185.0M | -$124.6M |
| Capital expenditures | $56.0K | $0 | $50.0K | $444.0K | $1.05M |
| Free cash flow | -$249.1M | -$131.8M | -$111.2M | -$185.5M | -$125.6M |
| Stock-based compensation | $33.9M | $41.4M | $24.9M | $28.6M | $22.7M |
| Investing cash flow | -$311.1M | -$248.5M | $39.0M | $96.9M | -$140.5M |
| Financing cash flow | $702.2M | $514.3M | $91.9M | $10.5M | $107.6M |
| Net change in cash | $142.0M | $134.1M | $19.7M | -$77.7M | -$157.5M |
| Ratio | |||||
| Stock-based compensation, % of revenue | – | 483.6% | 1015.8% | – | – |
Shares outstanding
Common shares outstanding as stated on the cover of each 10-K and 10-Q. The date is the cover date, not the period end; a rising count means dilution.
| Cover date | Shares outstanding | Change in a year | Filing |
|---|---|---|---|
| Nov 4, 2026 | 28.0M | +11.8% | SEC |
| Jul 31, 2026 | 27.9M | +32.7% | SEC |
| May 4, 2026 | 27.9M | +36.9% | SEC |
| Feb 16, 2026 | 27.9M | +38.1% | SEC |
| Oct 31, 2025 | 25.0M | +34.2% | SEC |
| Jul 31, 2025 | 21.0M | +18.5% | SEC |
| Apr 30, 2025 | 20.4M | +19.1% | SEC |
| Feb 26, 2025 | 20.2M | +52.3% | SEC |
Notes and known gaps
How these numbers are put together, and what they can't tell you.
- Numbers come from the XBRL data in each period's original 10-K, 10-Q, 20-F or 40-F, or its amendment. They are shown as filed: later filings don't restate earlier periods here.
- Reported is the filing date of the first 8-K with Item 2.02 (results of operations) after the period ended, no later than the 10-Q or 10-K and within 120 days. Companies that release results only in the 10-Q, and foreign companies, which use Form 6-K, have none.
Known gaps
- Foreign companies that file Form 20-F or 40-F have annual statements only: their quarterly results are furnished on Form 6-K, which has no XBRL data.
- EPS and share counts are as reported at the time, not adjusted for later stock splits. Stock splits since Dec 31, 2020, from 13F share counts: 1-for-15 in Q4 2023.
- For ADRs, EPS is per ordinary share, not per ADS (one TSMC ADS is five ordinary shares).
- For banks, revenue may be interest income only, depending on how the bank tags its filings; cost of revenue and gross profit are usually blank.
- Companies with several share classes, such as Berkshire Hathaway, may have no EPS and no cover share count.
- Depreciation and amortization is missing for some companies that report it under their own XBRL tags.